|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Adult Oncology, Dana Farber
Cancer Institute, and Department of Medicine, Harvard Medical School,
and Massachusetts Eye and Ear Infirmary, Harvard Medical School,
Boston, MA.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL, Apo2 ligand) effectively kills multiple myeloma (MM) cells in
vitro irrespective of refractoriness to dexamethasone and chemotherapy. Because clinical trials with this anticancer agent are expected shortly, we investigated the signaling pathway of TRAIL-induced apoptosis in MM. We detected rapid cleavage of caspases-8, -9, -3, and -6, as well as the caspase substrates poly(ADP-ribose) polymerase (PARP) and DNA fragmentation factor-45
(DFF45), but not caspase-10, upon TRAIL treatment in sensitive
MM cells, pointing to caspase-8 as the apical caspase of TRAIL
signaling in MM cells. These phenomena were not observed or
were significantly delayed in TRAIL-resistant MM cells,
suggesting that resistance may arise from inhibition at the level of
caspase-8 activation. Higher levels of expression for various apoptosis
inhibitors, including FLICE-inhibitory protein (FLIP), and lower
procaspase-8 levels were present in TRAIL-resistant cells and
sensitivity was restored by the protein synthesis inhibitor
cycloheximide (CHX) and the protein kinase C (PKC) inhibitor
bisindolylmaleimide (BIM), which both lowered FLIP and
cellular inhibitor of apoptosis protein-2 (cIAP-2)
protein levels. Forced expression of procaspase-8 or FLIP antisense
oligonucleotides also sensitized TRAIL-resistant cells to TRAIL.
Moreover, the cell permeable nuclear factor (NF)- Tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL/Apo2L) is a member of the superfamily
of cell death ligands, which also includes TNF- Recently, we showed that TRAIL induces apoptosis of human multiple
myeloma (MM) cell lines,13 as well as freshly obtained samples from patients with MM, and exhibits in vivo antimyeloma activity in nude mice xenografted with human
plasmacytomas.14 TRAIL spares normal peripheral blood B
cells and bone marrow mononuclear cells and imposes no significant
adverse effect on hematopoietic progenitors.14
Furthermore, TRAIL is active against dexamethasone- and cytotoxic drug-
resistant MM cells.14 Importantly, doxorubicin, peptide
inhibitors of nuclear translocation of nuclear factor (NF)- In the present study, we investigated the intracellular signaling of
TRAIL/Apo2L-induced apoptosis in MM cell lines and the mechanism(s) of
resistance. We found that TRAIL activates caspase-8 and
caspase-6, but not caspase-10, in sensitive MM cells. Caspase-9 and
caspase-3 are also activated, but are not necessary for the execution
of apoptosis. Resistance to TRAIL is due to lack of activation of
caspase-8 and is associated with a low procaspase-8/FLICE-inhibitory protein (FLIP) ratio. Consistent with this, down-regulation of FLIP by
antisense oligonucleotides or transfection of procaspase-8 sensitized
resistant MM cells to TRAIL. The protein synthesis inhibitor
cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM) down-regulated FLIP and
cIAP-2 levels and sensitized MM cells to TRAIL. The
cell-permeable NF- MM cell lines
As we have previously shown,14 MM-1S, MM-1R, RPMI-8226/S,
RPMI-Dox40, and ARP-1 cells are very sensitive to TRAIL/Apo2L-induced apoptosis (300 ng/mL for 18 hours induces > 60% apoptosis), whereas ARH-77, IM-9, and HS-Sultan cells exhibit only 15%, 3%, and 3% cell
death, respectively, under the same conditions. Therefore, ARH-77 cells
are deemed to be moderately and IM-9 and HS-Sultan cells highly
resistant to TRAIL, and as such these cell lines were used in this
study as a model of resistance to TRAIL/Apo2L. It should be noted,
however, that this resistance is not complete, because prolonged
exposure to higher concentrations of TRAIL leads to a modest loss of
viability, even in IM-9 and HS-Sultan cells.
All cell lines were cultured in RPMI 1640 medium (Gibco Laboratories,
Grand Island, NY) supplemented with 10% charcoal dextran-treated fetal
bovine serum (FBS; Hyclone, Logan, UT) as well as
L-glutamine, penicillin, and streptomycin (Gibco).
Materials
Immunoblot analysis Immunoblot analysis was performed as previously described.15 Briefly, cells were lysed for 30 minutes on ice in lysis buffer (50 mM Tris-HCl pH 8, with 120 mM NaCl and 1% NP-40) supplemented with the complete-TM mixture of proteinase inhibitors. The samples were cleared by microcentrifugation (14 000 rpm, 30 minutes, 4°C) and assessed for protein concentration. Thirty micrograms of the protein/sample were electrophoresed in a 12% SDS-polyacrylamide gel (SDS-PAGE), and electroblotted onto nitrocellulose membranes. After 1 hour incubation in blocking solution (20% IgG-free normal horse serum, in phosphate-buffered saline, PBS), the membranes were exposed overnight at 4°C to the primary antibody. Following washing in PBS, the respective secondary peroxidase-labeled antibody was applied at 1:10 000 dilution for 1 hour at room temperature. The proteins were visualized with the ECL technique.Cleavage of caspases, poly(ADP-ribose) polymerase, and DNA fragmentation factor-45 The involvement of caspases in TRAIL-induced apoptosis in MM cells was studied by evaluating the levels of procaspases-8, -10, -3, -6, and -9 as well as the emergence of their cleaved active forms by immunoblotting in lysates of cells treated with 300 ng/mL TRAIL for 0.5, 1, and 5 hours. Also, the cleavage of 2 known targets of caspase activity, poly(ADP-ribose) polymerase (PARP) and DNA fragmentation factor-45 (DFF45), were also studied in the same lysates.Caspase-3 activity assays The activity of caspase-3 was monitored in MM cells following treatment with 300 ng/mL TRAIL for 5 hours with the Caspase-3 Intracellular Activity Assay kit (Calbiochem, La Jolla, CA), according to the manufacturer's instructions. The assay depends on the detection of the cleavage of the peptide PhiPhiLux, which is mediated by caspase-3. When the peptide is cleaved, it provides an intense fluorescent signal.MTT colorimetric survival assays The effect of TRAIL on MM cell survival was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay, as previously described.15 Cells were plated in 48-well plates at 70% to 80% confluence and then incubated for 18 hours with LZ-TRAIL (100-300 ng/mL), in 2% bovine serum-supplemented RPMI medium at 37°C. Prior to exposure to TRAIL, MM cells were preincubated with caspase inhibitors (pancaspase inhibitor ZVAD-FMK, caspase-8 inhibitor IETD-FMK, caspase-3 inhibitor DEVD-FMK, caspase-9 inhibitor LEHD-FMK, and caspase-6 inhibitor VEID-FMK; all purchased from Calbiochem, and used at 20 µM) for 1 hour, or, in other experiments, with cycloheximide (0.1 µg/mL) or BIM (20 µM) for 6 hours. All experiments were repeated at least 3 times and each experimental condition was repeated at least in quadruplicate wells in each experiment. At the end of each treatment, cells were incubated with 1 mg/mL MTT in fresh media for 4 hours at 37°C, and then a mixture of isopropanol and 1N HCl (23:2, vol/vol) was added under vigorous pipetting to dissolve the formazan crystals. Dye absorbance in viable cells was measured at 570 nm, with 630 nm as a reference wavelength. Cell survival was estimated as a percentage of the value of untreated controls.Cloning and transfection of procaspase-8 into myeloma cells The full-length human procaspase-8 sequence was amplified by polymerase chain reaction using an HT29 colon carcinoma expression library cloned into the pCDM8 vector and appropriate synthetic oligonucleotide primers, corresponding to sequences encoding the amino- and carboxy-terminal extremities of the precursor protein, and cloned into the mammalian expression vector pcDNA3.1-TOPO-V5-His (Invitrogen, Carlsbad, CA). The correct orientation and sequence were verified by restriction analysis and dideoxy sequencing, respectively. IM-9 cells were transfected with the procaspase-8 construct or the empty vector with the help of Superfect (Qiagen, Valencia, CA) or left untreated. Forty-eight hours later, the cells were treated overnight with either TRAIL (200 ng/mL) or vehicle. Cell survival was quantified with the MTT assay.Transfection of FLIP antisense and control oligonucleotides To delineate the role of FLIP as a negative regulator of TRAIL-induced apoptosis, we transfected the TRAIL-resistant line IM-9, which expresses high levels of FLIP with fully phosphorothioated single-stranded ASO directed against the human FLIP translation initiation codon (sequence, 5'-GACTTCAGCAGACATCCTAC-3') or control phosphorothioate oligodeoxynucleotides (sequence, 5'-TGGATCCGACATGTCAGAGA-3'), as previously described by Perlman et al.16 IM-9 cells were plated in 24-well plates and transfected with the help of Oligofectamine (Gibco BRL, Gaithersburg, MD). Forty-eight hours later, TRAIL (200 ng/mL) was added to appropriate wells and the cells were incubated for an additional 18 hours. Cell death was quantified by MTT as described above.Caspase-8 activity assay The IM-9 cells were pretreated with CHX (0.1 µg/mL), BIM (20 µM), or SN50 (30 µg/mL) for 6 hours, and then stimulated with TRAIL (300 ng/mL) for 30 more minutes. The enzymatic activity of caspase-8 was measured with the ApoAlert caspase-8 colorimetric kit (Clontech, Palo Alto, CA), according to the manufacturer's instructions. Each experimental condition was performed both in the presence and absence of the caspase-8 inhibitor IETD-FMK (20 µM). The value obtained in the presence of IETD-FMK was subtracted from that obtained in its absence, to yield the caspase-8-specific activity of the sample.Flow cytometric analysis for TRAIL receptor expression The MM cell lines were characterized for their surface expression of TRAIL receptors by flow cytometry. Staining was performed as previously described.17 Briefly, for each cell line, 106 cells were incubated with the appropriate anti-TRAIL receptor antibody or a respective control (5.0 µg) for 45 minutes. Specifically, DR4 and DR5 expression was assessed with anti-DR4 and anti-DR5 monoclonal antibodies (mouse IgG1 and IgG2b as respective controls) and confirmed with goat antihuman DR4 and DR5 polyclonal antibodies, using goat IgG for control stainings. DcR1 and DcR2 expression was assessed with goat anti-DcR1 (or rabbit anti-DcR1) and goat anti-DcR2 polyclonal antibodies. Cells were then washed with PBS and incubated for 45 minutes with 2.0 µg goat antimouse IgG FITC-conjugated F(ab')2 fragment for anti-DR4 and anti-DR5 monoclonal antibody phenotypic analyses or with a donkey antigoat IgG FITC-conjugated F(ab')2 fragment for the DcR1, DcR2, DR4, and DR5 analyses with the goat polyclonal antibodies. Cells were then washed, fixed with 1% formaldehyde PBS, and analyzed on a EPICS-XL-MCL flow cytometer (Coulter, Hialeah, FL).Statistical analysis Statistical significance was examined by analysis of variance, followed by the Duncan posthoc test. P < .05 was considered consistent with statistical significance, in all analyses.
Immunoblot analysis for activation of caspases and cleavage of PARP and DFF45 in myeloma cells exhibiting differential sensitivities to TRAIL The proteolytic cleavage of caspase-8, -10, -9, and -3 and their substrates PARP and DFF45 were studied in TRAIL-sensitive (MM.1S), moderately resistant (ARH-77), and highly resistant (IM-9) cells that were treated with TRAIL (300 ng/mL) for 0.5, 1, and 5 hours. Rapid cleavage of procaspase-8 was detected in MM.1S cells (Figure 1), but not in ARH-77 or IM-9 cells. Interestingly, procaspase-10 was not cleaved in any cell line throughout the duration of the experiment, contrary to our previous finding of caspase-10 cleavage during TRAIL-induced apoptosis of thyroid carcinoma cells3 using the same antibody from Upstate Biotechnology. To confirm this finding, we used another antibody against a different epitope of caspase-10, which was obtained from Research Diagnostics, and compared our findings in TRAIL-treated MM and thyroid carcinoma cells (SW579 line). Once again, caspase-10 cleavage was detected with the Research Diagnostics antibody in TRAIL-treated thyroid carcinoma cells, but not in MM.1S cells (data not shown), thus confirming the specificity of our findings. These results, therefore, suggest that caspase-8, but not caspase-10, mediates TRAIL signaling in MM cells, and that there are tissue-dependent differences in the TRAIL signaling pathway.
Caspase-3 was also cleaved in TRAIL-treated MM.1S cells, but not to any significant degree in ARH-77 and IM-9 cells. A weak band of cleaved caspase-3 in ARH-77 was, however, detected at 5 hours after treatment with TRAIL only after prolonged film exposure. The same pattern was found for the caspase substrate PARP, with rapid complete cleavage in TRAIL-sensitive MM.1S cells, weak delayed cleavage in ARH-77, and lack of cleavage in IM-9 cells (Figure 1). The enzymatic activity of caspase-3 was also evaluated in the same cell
lines after 5 hours of TRAIL treatment (Figure
2). These studies demonstrated that TRAIL
induced a strong increase in the number of MM.1S cells that were
positive for caspase-3 activity and still retained intact cellular
membrane as evidenced by lack of propidium iodide uptake. In contrast,
only minor responses were detected in TRAIL-treated ARH-77 and IM-9
cells.
Caspase-6, another executioner caspase, was also rapidly cleaved in
MM1.S but not in ARH-77 or IM-9 cells treated with TRAIL (Figure
3). Caspase-9 similarly underwent rapid
cleavage in MM.1S cells (Figure 3). This effect was not detected in
ARH-77 or IM-9 cells, but both cell lines contained low but detectable
levels of cleaved caspase-9. It is possible that these cells maintain their viability by quenching the activity of caspase-9 with the help of
apoptosis inhibitors, potentially XIAP, which binds and inactivates
caspase-9.18 DFF45, another caspase substrate, was also
rapidly cleaved in MM.1S cells but not in ARH-77 or IM-9 cells (Figure
3).
These data therefore suggest that in TRAIL-sensitive MM cells a rapid activation of the caspase cascade occurs following TRAIL treatment, and that caspase-8 likely functions as the apical caspase in TRAIL-induced signaling in MM cells. In contrast, caspase-8 cleavage and ensuing downstream events are significantly delayed or absent in TRAIL-resistant cells, thereby suggesting that a potential antiapoptotic block takes place at the level of caspase-8 activation. Modulation of TRAIL-induced cytotoxicity in MM.1S myeloma cells by selective inhibition of caspases Because caspases are proteolytically cleaved and activated during TRAIL-induced apoptosis in MM cells, we next attempted to discern which caspases were indispensable for apoptotic signaling in MM. We therefore evaluated the effect of various caspase inhibitors (the pancaspase inhibitor ZVAD-FMK, the caspase-8 inhibitor IETD-FMK, the caspase-3/-7 inhibitor DEVD-FMK, the caspase-9 inhibitor LEHD-FMK, and the caspase-6 inhibitor VEID-FMK19) on TRAIL-induced apoptosis in MM.1S cells (Figure 4A). These studies showed that the pancaspase inhibitor ZVAD-FMK protected MM.1S cells from TRAIL-induced apoptosis, confirming that caspase activity was indispensable in TRAIL-induced apoptosis. Moreover, the caspase-8 inhibitor IETD-FMK also had a protective effect, confirming that caspase-8 activation is an integral part of this apoptotic pathway. In contrast, the caspase -3 and -7 inhibitor DEVD-FMK did not protect MM.1S cells from TRAIL. This suggests that the activation of the executioner caspases-3 and -7 is not critical for TRAIL-induced apoptosis in MM cells. The executioner caspase in this pathway appears to be caspase-6, because the caspase-6 inhibitor VEID-FMK also protected MM.1S cells from TRAIL-induced apoptosis. Interestingly, the function of caspase-9 appeared to be redundant because the caspase-9 inhibitor LEHD-FMK did not protect MM.1S cells from TRAIL-mediated apoptosis.
The finding that the caspase-3/-7 inhibitor DEVD-FMK did not protect MM.1S cells from TRAIL-induced apoptosis agrees with previous data in another model.20 Still, we wanted to confirm that this inhibitor is actually internalized by MM cells and does block caspase-3 activity. Therefore, we assessed caspase-3 activity in MM.1S cells, as previously, and found that DEVD-FMK indeed blocks caspase-3 activity in TRAIL-treated MM.1S cells (Figure 4B-D) and thus the negative data obtained with this compound are valid. Expression of intracellular regulators of apoptosis in TRAIL-sensitive and -resistant MM cells We next examined TRAIL-sensitive and -resistant MM cells for protein expression of several important proapoptotic and antiapoptotic regulators to discern differences that might account for variations in TRAIL sensitivity. Cell extracts from TRAIL-sensitive MM-1S, MM-1R, RPMI-8226/S, RPMI-Dox40, and ARP-1 cells; moderately TRAIL-resistant ARH-77 cells; and highly TRAIL-resistant IM-9 and HS-Sultan cells14 were examined by Western blot analysis for the presence of the proapoptotic molecules caspase-8 and FADD along with the intracellular apoptosis inhibitors FLIP, cIAP1, cIAP2, XIAP, and survivin. Although no differences in the expression of the proapoptotic protein FADD were observed among TRAIL-sensitive and -resistant cells, highly TRAIL-resistant HS-Sultan and IM-9 cells exhibited very low levels of the proapoptotic caspase-8 protein in comparison to TRAIL-sensitive and moderately TRAIL-resistant (ARH-77) cell lines. In addition, these studies showed that no single apoptosis inhibitor was per se correlated with resistance to TRAIL/Apo2L, though in general, higher levels of expression for the various apoptotic inhibitor proteins that we examined were present in TRAIL-resistant cells (Figure 5).
Increased expression of procaspase-8 sensitizes TRAIL-resistant MM cells to TRAIL Because very low levels of procaspase-8 were observed among highly TRAIL-resistant cells correlated with resistance to TRAIL, we next attempted to restore TRAIL sensitivity by overexpressing procaspase-8 in TRAIL-resistant IM-9 cells. As shown in Figure 6, transient expression of procaspase-8 restored TRAIL sensitivity of IM-9 cells, whereas untransfected or control vector-transfected IM-9 cells remained TRAIL resistant (Figure 6).
CHX and BIM down-regulate FLIP and cIAP2 expression and overcome TRAIL resistance in MM cells Previous studies have demonstrated that the activity of various proapoptotic agents can be enhanced following treatment with CHX, a protein synthesis inhibitor that can block expression of short-lived proteins including the antiapoptotic FLIP.21,22 As such, we examined whether treatment of TRAIL-resistant cells with CHX resulted in TRAIL-induced apoptosis. These studies showed that CHX did in fact sensitize highly TRAIL-resistant IM-9 cells to TRAIL (Figure 7A). Because highly TRAIL-resistant HS-Sultan and IM-9 cells expressed high FLIP protein levels, which mediate TRAIL resistance in mature dendritic cells,23 we next examined whether BIM, an agent known to down-regulate FLIP,22 similarly restored TRAIL sensitivity in highly TRAIL-resistant IM-9 cells. BIM, analogous to CHX, also restored TRAIL sensitivity to IM-9 cells (Figure 7A). Moreover, immunoblot analysis showed that both BIM and CHX down-regulated the protein levels of FLIP as well as cIAP2, but not those of Bcl-2 or Bcl-xL in IM-9 cells (Figure 7B).
Inhibition of FLIP expression with antisense oligonucleotides sensitizes TRAIL-resistant MM cells to TRAIL To more directly demonstrate a role for FLIP in mediating TRAIL resistance, highly TRAIL-resistant IM-9 cells were incubated with either control or antisense oligonucleotides directed at FLIP,16 and subsequently treated with TRAIL (200 ng/mL). These studies showed that incubation of cells with antisense oligonucleotides to FLIP sensitized IM-9 cells to TRAIL (Figure 8).
Modulation of apoptosis regulatory proteins by the NF-  B
inhibitor SN50 increased the sensitivity of TRAIL-sensitive MM cells (ie, MM.1S) to TRAIL, and restored TRAIL sensitivity to TRAIL-resistant cells (ARH-77, IM-9).14 As an extension of this work, we
next sought to identify the molecular target of SN50 in the apoptotic machinery. Cells (MM.1S, ARH-77, and IM-9) were treated for 6 hours
with the SN50 peptide (30 µg/mL), and protein levels of DR4, DR5,
DcR1, DcR2, procaspase-8, procaspase-10, procaspase-3, FLIP, cIAP1,
cIAP2, XIAP, survivin, Bcl-2, and Bcl-xL were then examined by
immunoblotting. As shown in Figure 9, the
increased response to TRAIL could not be attributed to changes in
levels of TRAIL receptor expression. In fact, a moderate decrease of DR4/DR5 was found in all cell lines examined (Figures 9 and
10), in agreement with a recent report
in another model,24 suggesting therefore that sensitivity
to TRAIL can be restored even in the presence of weak(er) DR4/DR5
receptor expression and that low-level expression of the TRAIL death
receptors does not necessarily account for lack of TRAIL activity in
certain tumor cells.
Among the other proapoptotic and antiapoptotic proteins studied, only
cIAP2 protein expression was significantly decreased after treatment
with the NF- Caspase-8 activation in TRAIL-resistant myeloma cells preincubated with CHX, BIM, or SN50 prior to TRAIL treatment Because CHX, BIM, and SN50 sensitized MM cells to TRAIL, and because these agents also down-regulated FLIP and cIAP2, we next determined whether these agents relieved inhibitors of caspase-8 processing and activation. As shown in Figure 11A, increased caspase-8 activity using the ApoAlert caspase-8 colorimetric kit was observed in IM-9 cells only when preincubated with CHX, BIM, or SN50 prior to TRAIL exposure. Moreover, caspase-8 cleavage was not induced by TRAIL treatment of control IM-9 cells, whereas caspase-8 cleavage was readily induced by TRAIL in IM-9 cells pretreated with CHX (not shown), BIM, or SN50 (Figure 11B). These studies therefore confirm the proapoptotic effect of CHX, BIM, and SN50, BIM at the level of caspase-8 activation, and further suggest that inhibition of procaspase-8 cleavage is a major mechanism of resistance to TRAIL in MM cells.
In the present study, we investigated the mechanism of TRAIL-induced apoptosis in MM. We found that cell death triggered by TRAIL is mediated by the activation of caspases-8 and -6. Caspases-3 and -9 were also cleaved and activated, yet their role appears to be dispensable. Resistance to TRAIL was associated with lack of cleavage of caspase-8 and downstream caspases, but could not be attributed solely to the presence of any single apoptosis inhibitor protein. However, diminished expression of the proapoptotic protein caspase-8 and expression of the apoptosis inhibitor proteins FLIP and cIAP2 were associated with decreased TRAIL sensitivity because overexpression of caspase-8 or inhibition of FLIP or cIAP2 restored sensitivity to TRAIL. Interestingly, the sensitization of resistant cells to TRAIL by either CHX, BIM, or SN50 resulted in activation of caspase-8 after TRAIL stimulation, thus confirming that inhibition of the apoptotic cascade in TRAIL-resistant cells rested at the level of caspase-8 cleavage. TRAIL is a member of the superfamily of TNF-related ligands that
potently induces apoptosis of a wide range of cancer cells, while
sparing normal cells.1-7,12,25-27 The temporary concerns raised by a report suggesting that recombinant TRAIL/Apo2L killed normal human hepatocytes in vitro28 were addressed by
subsequent studies that attributed it to nonoptimized recombinant
ligand preparations.29 Therefore, there is strong interest
for the upcoming phase I clinical trials of this anticancer
agent. We and others13,14,30-32 have
demonstrated that TRAIL induces apoptosis of MM cell lines and patient
tumor cells in vitro. Importantly, TRAIL sensitivity was noted even in
MM cells resistant to dexamethasone, melphalan, and adriamycin,
suggesting that TRAIL may be clinically active even in the setting of
MM refractory to conventional therapies. Five cell lines (ARH-77,
HS-Sultan, IM-9 and MM-AS, MM-SV), which are all CD20+ and
therefore likely to represent an earlier plasmacytic differentiation stage, showed significantly lower apoptotic responses to TRAIL than MM
cell lines that were CD20 Apoptosis induced by cell surface death receptors (eg, TNF-R1, Fas, DR4, DR5) is mediated by the recruitment and activation of an apical caspase (either caspase-8 or caspase-10) to the receptor, which subsequently activates downstream executioner caspases (caspase-3, -7, or -6). The mechanism of TRAIL-triggered signaling, as well as the identity of the apical caspase in the TRAIL pathway, are controversial. In contrast to Fas signaling where caspase-8 is unequivocally recruited to the receptor signaling complex and is the first caspase to be activated, both caspase-8 and caspase-10 have been implicated as the apical caspases of TRAIL-induced apoptosis. Specifically, interaction of caspase-10 with TRAIL receptors has been shown in cells cotransfected with plasmids encoding the respective genes,34 and we have recently shown recruitment of endogenous caspase-10 to the TRAIL receptor signaling complex in thyroid carcinomas3 and Ewing sarcomas.4 In contrast, studies in human lymphoid lines10,11 have shown recruitment of endogenous caspase-8 to the TRAIL-activated death receptors DR4 and DR5. In agreement with the latter studies on hematopoietic malignancies, we found that caspase-8, but not caspase-10, is proteolytically cleaved and the initiator caspase of the TRAIL pathway in MM. Therefore, it appears that the initial step of the apoptotic cascade triggered by TRAIL is tissue dependent. Previous studies on Fas-mediated apoptosis have shown that the death receptor-mediated autocatalytic cleavage of procaspase-8 can signal apoptosis via direct cleavage of caspase-3 and other executioner caspases (caspase-7, caspase-6).35 Additionally, caspase-8 can cleave Bid, a cytoplasmic member of the bcl-2 family, which induces the release of cytochrome c from mitochondria.36,37 Cytochrome c in complex with apoptotic protease-activating factor 1 (Apaf-1) activates caspase-9, which in turn activates the executioner caspases.38 This mitochondria-dependent pathway can be inhibited by bcl-2.39,40 Our data suggest that TRAIL-induced apoptosis in sensitive MM cells proceeds rapidly through cleavage of downstream caspases by caspase-8. The pivotal role of caspases is evidenced by the inhibitory effect of a pancaspase inhibitor, as well as by specific inhibitors for caspase-8 and caspase-6. Furthermore, the well-known caspase substrates PARP and DFF45 were rapidly cleaved in MM.1S cells on TRAIL treatment. PARP is the most widely used marker for the detection of caspase activity.41 DFF45 is the 45-kd inhibitory subunit of the heterodimeric DNA fragmentation factor (DFF), which is cleaved and inactivated by executioner caspases, thus allowing the enzymatically active 40-kd subunit, otherwise known as caspase-activated DNase (CAD), to translocate to the nucleus and mediate the degradation of genomic DNA.42,43 Activation of the mitochondrial pathway may also occur during TRAIL-induced apoptosis in MM cells, as evidenced by the cleavage of caspase-9. However, it appears that this pathway is redundant, because a caspase-9 inhibitor did not protect MM.1S cells from TRAIL-induced cell death. Moreover, in another study transfection of bcl-2 into TRAIL-sensitive RPMI 8226 cells, which blocks the release of cytochrome c from mitochondria, failed to protect against TRAIL.30 Caspase-3 activation also appears to be dispensable, because TRAIL-induced apoptosis was not attenuated by the caspase-3 inhibitor DEVD-FMK. Therefore, caspase-3 activation is a marker that correlates with cell sensitivity to TRAIL, but may also be functionally redundant. This supports previous data in other models of overlapping activation of alternative caspases.20,44 Moreover, caspase-7 is also inhibited by DEVD-FMK, excluding it as an executioner caspase in TRAIL-induced apoptosis in MM. In contrast, caspase-6 is a candidate executioner caspase, because a caspase-6-specific inhibitor protected MM cells from TRAIL. Procaspase-8 cleavage, as well as cleavage of all other downstream caspases and caspase substrates, was significantly inhibited or even absent in TRAIL-resistant cells. This provided the first piece of evidence for the existence of an antiapoptotic block at the level of caspase-8 activation. To identify possible reasons for the inefficient activation of caspase-8, a panel of cell lines with high (MM-1S, MM-1R, RPMI-8226/S, RPMI-Dox40, and ARP-1), low (ARH-77), and no (IM-9, HS-Sultan) sensitivity to TRAIL were examined by immunoblotting for the presence of the apoptosis inhibitors FLIP, cIAP1, cIAP2, XIAP, and survivin, as well as for caspase-8 and the adaptor molecule FADD. Although expression of no single apoptosis inhibitor per se correlated with resistance to TRAIL/Apo2L, there was a tendency for higher levels of the various apoptotic inhibitors, in particular FLIP, and lower levels of procaspase-8 in the cell lines with lower response to TRAIL. Moreover, restoration of high protein levels of procaspase-8 by forced expression sensitized IM-9 cell to TRAIL. The identification of low procaspase-8 levels along with FLIP expression in highly TRAIL-resistant cells led us to study the effect of 2 more compounds on TRAIL-induced apoptosis of MM cells. CHX and BIM have been previously shown to overcome resistance to Fas-induced apoptosis,3,21,22,45 likely due to down-regulation of FLIP protein levels.21,22 In this study, we extended their use in TRAIL signaling and found that both can overcome the resistance of IM-9 cells to TRAIL. Importantly, both CHX and BIM down-regulated FLIP and cIAP2 protein levels, but not cIAP1, Bcl-2 or Bcl-xL. Using an antisense oligonucleotide, we then specifically lowered FLIP protein expression in IM-9 cells, which sensitized these cells to TRAIL, thereby confirming the protective role of FLIP against TRAIL-induced apoptosis. Although the inhibitory role of FLIP in Fas signaling is established, its role in TRAIL-induced apoptosis has been controversial, because elevated FLIP levels have been correlated with susceptibility to TRAIL in some,12,46 but not all, studies.47 Because the antiapoptotic role of FLIP depends on its recruitment to receptor complexes through FADD and procaspase-8 binding, which occurs in some but not all malignancies,3,4,34,46,48-51 it is possible that FLIP may exert an inhibitory role on TRAIL signaling in some, but not all, tissues. Alternatively, equal levels of FLIP may be inhibitory only in tumors with low death receptor and procaspase-8 levels, as demonstrated previously in another model39 and shown for IM-9 and HS-Sultan cells in our study. We have previously shown that SN50, a cell permeable inhibitor of
the nuclear translocation and transcriptional activity of NF- Finally, to confirm that the inhibitory activity of FLIP and cIAP2 on TRAIL-induced apoptosis is exerted at the level of procaspase-8 cleavage, we pretreated TRAIL-resistant cells with CHX, BIM, or SN50, and then stimulated them with TRAIL. We found that cleavage and enzymatic activation of procaspase-8 on stimulation with TRAIL occurred only in cells that had been pretreated with CHX, BIM, or SN50. This proves that the observed sensitization to TRAIL by these compounds is due to their effect on the processing of procaspase-8 and, furthermore, that the inhibition of caspase-8 activation is a major mechanism of TRAIL-resistance in MM cells. In summary, the potent antimyeloma activity of TRAIL/Apo2L is mediated
by the rapid activation of caspase-8, followed by caspase-6. Low levels
of procaspase-8, as well as the antiapoptotic function of FLIP and
cIAP2, may hinder caspase-8 activation, and thereby confer resistance
to TRAIL/Apo2L. Pharmacologic agents that down-regulate FLIP and cIAP2,
such as inhibitors of NF-
Submitted March 28, 2001; accepted October 12, 2001.
Supported by the Laurie Strauss Leukemia Foundation (N.M., C.S.M.), the Multiple Myeloma Research Foundation (N.M., C.S.M., S.P.T.), the Bailey Family Research Fund (N.M., C.S.M.), a National Institutes of Health Career Development Award (S.P.T.), and the Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Steven P. Treon, Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Mayer Bldg, Rm M557, Boston MA 02115; e-mail: steven_treon{at}dfci.harvard.edu.
1.
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A.
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem.
1996;271:12687-12690 2. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682[CrossRef][Medline] [Order article via Infotrieve].
3.
Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Cancer Res.
2000;60:4122-4129
4.
Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors.
Cancer Res.
2001;61:2704-2712 5. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255-260[CrossRef][Medline] [Order article via Infotrieve]. 6. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163[CrossRef][Medline] [Order article via Infotrieve]. 7. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162[Medline] [Order article via Infotrieve]. 8. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563[CrossRef][Medline] [Order article via Infotrieve]. 9. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem. 1998;254:439-459[Medline] [Order article via Infotrieve]. 10. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611-620[CrossRef][Medline] [Order article via Infotrieve]. 11. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599-609[CrossRef][Medline] [Order article via Infotrieve].
12.
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ.
Intracellular regulation of TRAILinduced apoptosis in human melanoma cells.
J Immunol.
1998;161:2833-2840 13. Treon SP, Chauhan D, Raje N, Teoh G, Webb I, Anderson KC. Recombinant human TNF-related apoptosis inducing ligand (hu TRAIL) induces apoptosis of human multiple myeloma (MM) cells. Blood. 1998;92:634a.
14.
Mitsiades CS, Treon SP, Mitsiades N, et al.
TNF-related apoptosis-inducing ligand/Apo2L selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood.
2001;98:795-804
15.
Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M.
Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.
Am J Pathol.
1998;153:1947-1956
16.
Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM.
FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis.
J Exp Med.
1999;190:1679-1688
17.
Treon SP, Mollick JA, Urashima M, et al.
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.
Blood.
1999;93:1287-1298
18.
Datta R, Oki E, Endo K, Biedermann V, Ren J, Kufe D.
XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage.
J Biol Chem.
2000;275:31733-31738
19.
Hirata H, Takahashi A, Kobayashi S, et al.
Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis.
J Exp Med.
1998;187:587-600 20. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene. 2000;19:3363-3371[CrossRef][Medline] [Order article via Infotrieve].
21.
Mueller CM, Scott DW.
Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells.
J Immunol.
2000;165:1854-1862
22.
Willems F, Amraoui Z, Vanderheyde N, et al.
Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide.
Blood.
2000;95:3478-3482
23.
Leverkus M, Walczak H, McLellan A, et al.
Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis.
Blood.
2000;96:2628-2631 24. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol. 2001;3:409-416[CrossRef][Medline] [Order article via Infotrieve]. 25. Rieger J, Ohgaki H, Kleihues P, Weller M. Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol (Berl). 1999;97:1-4[CrossRef][Medline] [Order article via Infotrieve]. 26. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 1998;427:124-128[CrossRef][Medline] [Order article via Infotrieve].
27.
Thomas WD, Hersey P.
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells.
J Immunol.
1998;161:2195-2200 28. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000;6:564-567[CrossRef][Medline] [Order article via Infotrieve]. 29. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001;7:383-385[CrossRef][Medline] [Order article via Infotrieve]. 30. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine. 1999;11:1010-1019[CrossRef][Medline] [Order article via Infotrieve]. 31. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824[CrossRef][Medline] [Order article via Infotrieve]. 32. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics [review]. Int J Oncol. 1999;15:793-802[Medline] [Order article via Infotrieve]. 33. Mitsiades CS, Mitsiades NS, Anderson KC, Treon SP. TRAIL induces differentiation-stage specific apoptosis in B-cell malignancies, overcomes drug resistance in multiple myeloma and its antimyeloma effect is enhanced by doxorubicin NF-kB inhibition. Proc Am Assoc Cancer Res. 2001;42:348.
34.
Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM.
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
Science.
1997;277:815-818 35. Schlottmann K, Coggeshall K. CD95/Fas/Apo-1 mediated signal tranduction. Cell Physiol Biochem. 1996;6:345-360[CrossRef]. 36. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490[CrossRef][Medline] [Order article via Infotrieve]. 37. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501[CrossRef][Medline] [Order article via Infotrieve].
38.
Zou H, Li Y, Liu X, Wang X.
An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9.
J Biol Chem.
1999;274:11549-11556 39. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675-1687[CrossRef][Medline] [Order article via Infotrieve].
40.
Poulaki V, Mitsiades N, Romero ME, Tsokos M.
Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2.
Cancer Res.
2001;61:4864-4872 41. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81:801-809[CrossRef][Medline] [Order article via Infotrieve]. 42. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 1997;89:175-184[CrossRef][Medline] [Order article via Infotrieve].
43.
Liu X, Li P, Widlak P, et al.
The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis.
Proc Natl Acad Sci U S A.
1998;95:8461-8466 44. Zheng TS, Hunot S, Kuida K, et al. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med. 2000;6:1241-1247[CrossRef][Medline] [Order article via Infotrieve].
45.
Mitsiades N, Poulaki V, Mastorakos G, et al.
Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
J Clin Endocrinol Metab.
1999;84:2924-2932 46. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195[CrossRef][Medline] [Order article via Infotrieve].
47.
Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P.
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.
Cancer Res.
1999;59:2747-2753
48.
Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME.
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells.
J Biol Chem.
1999;274:22532-22538
49.
Hu S, Vincenz C, Ni J, Gentz R, Dixit VM.
I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis.
J Biol Chem.
1997;272:17255-17257
50.
Pan G, O'Rourke K, Chinnaiyan AM, et al.
The receptor for the cytotoxic ligand TRAIL.
Science.
1997;276:111-113
51.
Lin Y, Devin A, Cook A, et al.
The death domain kinase RIP is essential for TRAIL (Apo2L)induced activation of IkappaB kinase and c-Jun N-terminal kinase.
Mol Cell Biol.
2000;20:6638-6645
52.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS.
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science.
1998;281:1680-1683
53.
Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW.
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.
Proc Natl Acad Sci U S A.
1997;94:10057-10062
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Baritaki, K. Yeung, M. Palladino, J. Berenson, and B. Bonavida Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Cancer Res., November 1, 2009; 69(21): 8376 - 8385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, E. M. Ocio, A. Pandiella, P. Maiso, C. Gajate, M. Garayoa, D. Vilanova, J. C. Montero, N. Mitsiades, C. J. McMullan, et al. Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo Cancer Res., July 1, 2008; 68(13): 5216 - 5225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells J. Immunol., May 1, 2008; 180(9): 6199 - 6210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suvannasankha, C. D. Crean, R. Shanmugam, S. S. Farag, R. Abonour, H. S. Boswell, and H. Nakshatri Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide Clin. Cancer Res., March 15, 2008; 14(6): 1814 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP J. Immunol., February 1, 2008; 180(3): 1545 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. Xu, N. Jhala, P. Pawar, Z. B. Zhu, L. Ma, C.-H. Byon, and J. M. McDonald Fas-Mediated Apoptosis in Cholangiocarcinoma Cells Is Enhanced by 3,3'-Diindolylmethane through Inhibition of AKT Signaling and FLICE-Like Inhibitory Protein Am. J. Pathol., November 1, 2006; 169(5): 1833 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Menoret, P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J.-L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells Blood, August 15, 2006; 108(4): 1346 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, R. C. Budd, R. J. Kelm Jr, B. E. Sobel, and D. J. Schneider Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1 Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1777 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Song, N. Benhaga, R. L. Anderson, and R. Khosravi-Far Transduction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand into Hematopoietic Cells Leads to Inhibition of Syngeneic Tumor Growth In vivo. Cancer Res., June 15, 2006; 66(12): 6304 - 6311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al. Antimyeloma activity of heat shock protein-90 inhibition Blood, February 1, 2006; 107(3): 1092 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhang, H.-M. Shen, and C. N. Ong Down-regulation of c-FLIP contributes to the sensitization effect of 3,3'-diindolylmethane on TRAIL-induced apoptosis in cancer cells Mol. Cancer Ther., December 1, 2005; 4(12): 1972 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Thomas, M. L. Sos, T. Zander, O. Mani, A. Popov, D. Berenbrinker, S. Smola-Hess, J. L. Schultze, and J. Wolf Inhibition of Nuclear Translocation of Nuclear Factor-{kappa}B Despite Lack of Functional I{kappa}B{alpha} Protein Overcomes Multiple Defects in Apoptosis Signaling in Human B-Cell Malignancies Clin. Cancer Res., November 15, 2005; 11(22): 8186 - 8194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, H. Li, M. Derouet, J. Filmus, E. C. LaCasse, R. G. Korneluk, R. S. Kerbel, and K. V. Rosen ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells: EPIDERMAL GROWTH FACTOR RECEPTOR-DEPENDENT AND -INDEPENDENT MECHANISMS OF ras-INDUCED TRANSFORMATION J. Biol. Chem., November 11, 2005; 280(45): 37383 - 37392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Evens, P. Lecane, D. Magda, S. Prachand, S. Singhal, J. Nelson, R. A. Miller, R. B. Gartenhaus, and L. I. Gordon Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells Blood, February 1, 2005; 105(3): 1265 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Crowder, O. Dahle, R. E. Davis, O. S. Gabrielsen, and S. Rudikoff PML mediates IFN-{alpha}-induced apoptosis in myeloma by regulating TRAIL induction Blood, February 1, 2005; 105(3): 1280 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, C. S. Mitsiades, C. McMullan, G. Fanourakis, J. Negri, A. Goudopoulou, I. X. Halikias, G. Voutsinas, S. Tseleni-Balafouta, J. W. Miller, et al. Human Retinoblastoma Cells Are Resistant to Apoptosis Induced by Death Receptors: Role of Caspase-8 Gene Silencing Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ruiz-Ruiz, C. Ruiz de Almodovar, A. Rodriguez, G. Ortiz-Ferron, J. M. Redondo, and A. Lopez-Rivas The Up-regulation of Human Caspase-8 by Interferon-{gamma} in Breast Tumor Cells Requires the Induction and Action of the Transcription Factor Interferon Regulatory Factor-1 J. Biol. Chem., May 7, 2004; 279(19): 19712 - 19720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Anderson Proteasome inhibitor therapy of multiple myeloma. AACR Meeting Abstracts, March 1, 2004; 2004(1): 1316 - 1316. [Abstract]
|
|
|
|
 |
|
 C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, T. Hideshima, M. Akiyama, D. Chauhan, N. Munshi, X. Gu, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications PNAS, January 13, 2004; 101(2): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, N. S. Mitsiades, R. T. Bronson, D. Chauhan, N. Munshi, S. P. Treon, C. A. Maxwell, L. Pilarski, T. Hideshima, R. M. Hoffman, et al. Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications Cancer Res., October 15, 2003; 63(20): 6689 - 6696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, P. G. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. C. Munshi, T. Hideshima, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood, May 15, 2003; 101(10): 4055 - 4062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, S. Hilsenbeck, and Y. Gazitt Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL Blood, May 15, 2003; 101(10): 4078 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wajant Targeting the FLICE Inhibitory Protein (FLIP) in Cancer Therapy Mol. Interv., May 1, 2003; 3(3): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, S. P. Treon, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells PNAS, October 29, 2002; 99(22): 14374 - 14379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Spencer, S.-L. Yeh, K. Koutrevelis, C. Baulch-Brown ;, N. Mitsiades, C. Mitsiades, K. C. Anderson, and S. P. Treon TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio Blood, September 26, 2002; 100(8): 3049 - 3050. [Full Text] [PDF]
|
|
|
|
|
|
V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells Am. J. Pathol., August 1, 2002; 161(2): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. C. Munshi, S. P. Treon, and K. C. Anderson Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood, May 29, 2002; 99(12): 4525 - 4530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. Munshi, S. P. Treon, and K. C. Anderson Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications Blood, May 13, 2002; 99(11): 4079 - 4086. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
and Fas ligand (FasL
or CD95L).
(eg, MM.1S, MM.1R, RPMI-8226/S,
RPMI-Dox40).